Formulation of Ambient Temperature and Humidity Stable Rabies Vaccines
环境温度和湿度稳定的狂犬病疫苗的配制
基本信息
- 批准号:8088192
- 负责人:
- 金额:$ 63.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-06-01 至 2014-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcidsAlginatesAmericasAnimalsBile AcidsBiologicalBiological PreservationBiteCanis familiarisCell NucleusCenters for Disease Control and Prevention (U.S.)Cessation of lifeChemicalsChiropteraCoyotesDevelopmentDiseaseDisease VectorsDomestic AnimalsDrug FormulationsEatingElementsEncapsulatedEnvironmentFelis catusFerretsFoodFoxesGastric JuiceGastrointestinal tract structureGelGlassGoalsHealthHeatingHourHumanHumidityImmune responseIntestinal MucosaIntestinesLegal patentLiving CostsMeasuresMephitidaeMicrospheresMucous MembraneOilsOral cavityPharyngeal structurePhasePreventiveRabiesRabies VaccinesRaccoonsSalivaSmall IntestinesStomachSunlightTechnologyTemperatureVaccinationVaccine DesignVaccinesVacciniaVacciniumWild Animalsbaseferalnoveloral vaccinevaccine efficacyvaporization
项目摘要
DESCRIPTION (provided by applicant): Rabies is a deadly disease, estimated to cause 40-70 thousand deaths per year. It is most often spread by a bite and saliva from an infected wild or feral animal (e.g., bats, raccoons, skunks, foxes, ferrets, cats, or dogs). Oral vaccines in bait have been successful with animals that chew their food, thus allowing the vaccine bait to come into contact with the mouth and throat mucosa to elicit the immune response. However, canid species (dogs, foxes, coyotes) ,the primary vectors of the disease to humans, do not chew their food or the bait; rather it gulped down causing the vaccine to be destroyed in the stomach acid.
For our Phase 1 project, we combined two technologies to prepare a novel form of rabies vaccine, designed to be stable at ambient temperatures and in harsh environments, such as during the journey through stomach acid and bile secretion on its way to the small intestine where we propose it can immunize the animal through the intestinal mucosa. The PI's patent pending "Preservation by Vaporization" (PBV) technology which immobilizes sensitive biologicals in the "glass state" so they are stable at ambient temperatures has been utilized with alginate gel encapsulation to protect vaccines from heat and chemical damage. UST utilized PBV to dry-preserve two alginate-encapsulated vaccines VRG (vaccinia-based) and ERA (Rabies based). We exceeded our original target specifications for vaccine stability during 1 hour equilibration at 60¿C, and after 2 weeks at 37¿C.
The specific aims of the Phase II project are to: 1) Optimize formulation of dry preserved rabies vaccines encapsulated in alginate gel microspheres. 2) Formulate Rabies Vaccine Animal Bait Nucleus (RVABN) filled with VRG and with ERA vaccines. 3) Evaluate efficacy of the vaccine products in animal studies - specifically foxes and dogs - against a rabies challenge.
The long-range goal of this project is to produce an oral vaccine for rabies secreted in bait that is stable in the wild. This vaccine, once eaten by wild animals will not be destroyed in the GI tract and will produce a strong immune response in the intestine. UST will partner with CDC and Merial Ltd. who will provide the vaccine and help to perform animal studies.
PUBLIC HEALTH RELEVANCE: The number of deaths that rabies causes each year is estimated to be between 40,000- 70,000. The cost of living with rabies in America is high and growing, exceeding $300 million per year. Although rabies vaccinations have been available for domestic animals for many years, only recently have such preventive measures been developed to control rabies in wildlife. Development of baits that would have stable rabies vaccines embedded in edible hydrogenated oils such that the vaccines are protected from the elements, including sunlight, temperature, humidity and gastric juices, could allow vaccination of wild animals so they do not get rabies, and thus could help eradicate the disease.
描述(由申请人证明):狂犬病是一种致命的疾病,估计会导致40-7万人死亡。 。
对于我们的第1阶段项目,我们将两种技术组合在一起,以准备狂犬病疫苗SH环境的阳离子,例如在通过胃酸胆汁分泌的过程中,我们提出的是肠道粘膜,而PI的专利持续存在。 “通过汽化保存”将敏感的生物学固定在“因此,在环境温度下的稳定性已经与appulati一起使用,以保护疫苗免受热和化学损害。UST利用PBV来干燥两种藻类疫苗VRG(vaccinia vrg(vaccinia bassed bassed bassed bassed) )。 c,在37讲2周后C
II期项目的具体目的是:1)在藻酸盐凝胶微孔中封装的干燥保留疫苗的配方。动物研究 - 特定于狐狸和狗 - 激发狂犬病挑战。
在野生诱饵表中生产狂犬病稳定的远程疫苗将不会在胃肠道中设计,并且会在与CDC和Merial Ltd的伴侣中产生强大的IMUNE响应。将提供疫苗并有助于进行动物研究。
公共卫生相关性:AM Erica的生活成本很高,并且增长了3亿美元的peries疫苗接种多年,直到最近才制定了这种措施来控制野生动物的狂犬病。这种疫苗受到保护,免受元素,温度中度和胃果汁的保护,可以允许疫苗使疫苗不受狂犬病,因此可以帮助eeracite疾病。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Victor Bronshtein其他文献
Victor Bronshtein的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Victor Bronshtein', 18)}}的其他基金
Thermostable Inactivated Potent Yellow Fever Vaccine
耐热灭活强效黄热病疫苗
- 批准号:
10437039 - 财政年份:2021
- 资助金额:
$ 63.4万 - 项目类别:
Development of a thermostable rotavirus vaccine for mucosal delivery without need for reconstitution
开发用于粘膜递送且无需重构的热稳定性轮状病毒疫苗
- 批准号:
8903047 - 财政年份:2015
- 资助金额:
$ 63.4万 - 项目类别:
Development of a thermostable rotavirus vaccine for mucosal delivery withoutneed for reconstitution - Phase II
开发用于粘膜递送且无需重构的热稳定轮状病毒疫苗 - 第二阶段
- 批准号:
9348073 - 财政年份:2015
- 资助金额:
$ 63.4万 - 项目类别:
Formulation of Ambient Temperature and Humidity Stable Rabies Vaccines for Oral D
环境温度和湿度稳定的口服 D 型狂犬病疫苗的配制
- 批准号:
8000516 - 财政年份:2008
- 资助金额:
$ 63.4万 - 项目类别:
Formulation of Ambient Temperature and Humidity Stable Rabies Vaccines for Oral D
环境温度和湿度稳定的口服 D 型狂犬病疫苗的配制
- 批准号:
7538049 - 财政年份:2008
- 资助金额:
$ 63.4万 - 项目类别:
Stable Micronized Vaccines Against Smallpox and Japanese Encephalitis
针对天花和日本脑炎的稳定微粉化疫苗
- 批准号:
7134299 - 财政年份:2006
- 资助金额:
$ 63.4万 - 项目类别:
相似国自然基金
用于肥厚型心肌病介入治疗的凝血酶-海藻酸盐复合微球消融剂制备机制及其作用机制研究
- 批准号:
- 批准年份:2020
- 资助金额:55 万元
- 项目类别:
组织工程用氧化海藻酸盐/聚丙烯酰胺互穿网络均相凝胶的构建、结构与性能研究
- 批准号:
- 批准年份:2019
- 资助金额:41 万元
- 项目类别:地区科学基金项目
金属离子诱导海藻酸盐凝胶多尺度微观结构及外场下的演变机制
- 批准号:51803101
- 批准年份:2018
- 资助金额:26.0 万元
- 项目类别:青年科学基金项目
基于两亲性海藻酸盐的载药乳液的微观机制和多尺度模拟
- 批准号:21706045
- 批准年份:2017
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
两性离子聚合物/海藻酸锆互穿网络多孔凝胶球的构建及其吸附水中磷酸盐机理研究
- 批准号:51608133
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Microstructural Cues for the Treatment of Heart Failure
治疗心力衰竭的微观结构线索
- 批准号:
10078623 - 财政年份:2017
- 资助金额:
$ 63.4万 - 项目类别:
PepT1-/- microbiota therapy as a treatment for colitis
PepT1-/- 微生物群疗法作为结肠炎的治疗方法
- 批准号:
10363142 - 财政年份:2014
- 资助金额:
$ 63.4万 - 项目类别:
Controlling IGF-I/Scaffold Binding to Enhance Gene Therapy for Cartilage Repair
控制 IGF-I/支架结合以增强软骨修复的基因治疗
- 批准号:
8513929 - 财政年份:2011
- 资助金额:
$ 63.4万 - 项目类别:
Controlling IGF-I/Scaffold Binding to Enhance Gene Therapy for Cartilage Repair
控制 IGF-I/支架结合以增强软骨修复的基因治疗
- 批准号:
8205371 - 财政年份:2011
- 资助金额:
$ 63.4万 - 项目类别:
Controlling IGF-I/Scaffold Binding to Enhance Gene Therapy for Cartilage Repair
控制 IGF-I/支架结合以增强软骨修复的基因治疗
- 批准号:
8504681 - 财政年份:2011
- 资助金额:
$ 63.4万 - 项目类别: